Literature DB >> 1796555

[Determination of anti-arrhythmia therapy of ventricular arrhythmias based on programmed ventricular stimulation].

M Herold1, S Hrdlicka, P Osmera, P Gregor.   

Abstract

The authors used programmed ventricular stimulation in 38 patients who had during Holter monitoring severe ventricular arrhythmias (greater than or equal to Lown 4a). The group comprised patients with IHD (22x), hypertrophic (11x) and dilatating cardiomyopathy (2x). Three patients had no organic heart disease. Nine patients were treated at the time of examination with antiarrhythmic drugs. In a total of 16 patients it proved possible to provoke ventricular tachycardia (VT)--four times permanent ventricular tachycardia, 12x transient ventricular tachycardia (NSVT). In the group of treated patients SVT was provoked twice and NSVT also twice, always in patients who took amiodarone. Using programmed ventricular stimulation the following antiarrhythmic drugs were tested: mexiletine, cordarone, ajmaline. The capacity of all tested antiarrhythmics in the prevention of VT was comparable. A total of two patients died during the investigation, in both cases a sudden death. One suffered from hypertrophic cardiomyopathy, one from IHD. In both on Holter monitoring NSVT episodes were revealed. Programmed stimulation provoked in both SVT, both were treated at the time of death with tested antiarrhythmics. The authors conclude that programmed ventricular stimulation is a suitable method for rationalization of antiarrhythmic treatment, the clinical results, however, do not correspond to laboratory results. They recommend therefore to use also Holter monitoring of patients at risk.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1796555

Source DB:  PubMed          Journal:  Vnitr Lek        ISSN: 0042-773X


  1 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.